ArticleNature communications2025
mRNABERT: advancing mRNA sequence design with a universal language model and comprehensive dataset.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Allele-resolved monosome and polysome sequencing identifies cis-variants affecting mRNA translation.Life science alliance · 2026Article
- ContiTE: continuous manifold MoE for few-shot cross-tissue mRNA translation efficiency prediction.Briefings in bioinformatics · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Designing effective mRNA sequences for therapeutics remains a formidable challenge. Inspired by successes in protein design, language models (LMs) are now being applied to RNA, but progress is often impeded by the lack of comprehensive training data. Existing models are frequently limited to UTR or CDS regions, restricting their application for complete mRNA sequences. We introduce mRNABERT, a robust, all-in-one mRNA designer pre-trained on the largest available mRNA dataset. To enhance performance, we propose a dual tokenization scheme with a cross-modality contrastive learning framework to integrate semantic information from protein sequences. On a comprehensive benchmark, mRNABERT demonstrates state-of-the-art performance, outperforming previous models in the majority of tasks for 5' UTR and CDS design, RNA-binding protein (RBP) site prediction, and full-length mRNA property prediction. It also surpasses large protein models in several related tasks. In conclusion, mRNABERT's superior performance across these diverse tasks signifies a substantial leap forward in mRNA research and therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.